drugset / Trial / NCT06226610
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Phase 2
Recruiting
46 enrolled
Akron Children's Hospital
Ohio State University · collabRegeneron Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Timeline
- Start
- 2024-11-21
- Primary completion
- 2026-01-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.